TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
To the Copenhagen Stock Exchange
Announcement No. 05-07 / Copenhagen 26 March 2007
Notice of the Annual General Meeting
Notice is hereby given that the Annual General Meeting of TopoTarget A/S will
be held on:
Wednesday 11 April 2007 at 4.00 pm
The Annual General Meeting will be held at:
Axelborg, Vesterbrogade 4A, DK-1620 Copenhagen V, Denmark
The agenda for the Annual General Meeting is as follows:
1. The Board of Directors' report on the company's activities during the past
year.
2. Presentation of the revised annual report with auditor's report for adoption
and notification of decharge to the Board of Directors.
3. Resolution on application of profits or covering of losses as per the
adopted annual report.
4. Election of Board Members and alternates, if any.
5. Election of state authorised public accountant.
6. Other proposals from the Board of Directors and/or shareholders.
Re 6 - Authorisation to the Board of Directors to allow the company purchase
own shares
The Board of Directors proposes that the Board of Directors according to the
Companies Act section 48 is authorised to allow the company to purchase own
shares within the 10% limit as set out in section 48. The shares can be
pur-chased at a price corresponding to the listed price plus/minus 5% at the
time of the purchase. The authorisation shall be applicable until and including
the company's annual general meeting in 2008.
Re 6 - Authorisation to the Board of Directors to issue warrants.The Board of
Directors proposes that the Board of Directors until 1 March 2012 is
authorised, at one or more times, to issue up to 1,000,000 warrants, each
conferring a right to subscribe for 1 share of nominal DKK 1 in the company,
and to implement the corresponding increase of the share capital. The warrants
can be issued to employees, executive directors, board members, consultants and
advisors to the company and its subsidiaries without pre-emptive subscrip-tion
rights for the company's shareholders.
The exercise price for warrants which are issued pursuant to the authorisation
shall at a minimum correspond to the market price of the company's shares on
the date of issuance of the warrants. The other terms for the warrants issued
pursuant to this authorisation shall be determined by the Board of Directors.
*****
It is noted that the adoption of the proposals for amendments to the Articles
of Association on the agenda requires that the resolution is approved by at
least two thirds of the votes given and two thirds of the votes represented at
the general meeting.
The agenda and the complete proposed resolutions will be available for
inspec-tion at the company's office c/o Symbion, Fruebjergvej 3, 2100
Copenhagen Ø not later than eight days before the Annual General Meeting, and
will not later than eight days before the Annual General Meeting be sent to any
recorded shareholder who has requested so.
Registered shareholders will receive a request form for an admission card.
Shareholders, who are not registered, may request admission cards from
TopoTarget´s office on all weekdays (Saturdays excepted) in accordance with
article 12 of the Articles of Association. Admission cards may also be ordered
directly at www.topotarget.com.
TopoTarget will be serving light refreshments after the Annual General
Meet-ing.
The annual report 2006 will be sent to registered shareholders on 28 March
2007.
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Background information
About TopoTarget
TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company,
head-quartered in Denmark and with subsidiaries in the UK, Germany and the USA,
dedicated to finding ''Answers for Cancer'' and developing improved cancer
therapies. TopoTarget is founded and run by clinical cancer specialists and
combines years of hands-on clinical experience with in-depth understanding of
the molecular mechanisms of cancer. Focus lies on highly predictive cancer
models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase
II inhibitors) and a strong development foundation has been built. TopoTarget
has a broad portfolio of small molecule preclinical drug candidates and seven
drugs are in clinical development, including both novel anti-cancer
therapeutics and new cancer indications for existing drugs. Savene™ is
TopoTarget's first product on the market. In addition to organic growth,
TopoTarget consistently looks for opportuni-ties to strengthen and expand its
activities through acquisitions and in-licensing. For more information, please
refer to www.topotarget.com
